HAYWARD, Calif., March 22 /PRNewswire-FirstCall/ -- Cholestech Corporation , a leading manufacturer of point of care testing devices, today announced that Ken Miller, Vice President of Sales and Marketing will present at the Sidoti & Company Emerging Growth Institutional Investor Conference on Tuesday, March 27, 2007, at 2:05 p.m. Eastern Time in New York, NY. The presentation will include an overview of the company, current products, product pipeline and recent financial performance.
Cholestech is committed to enabling people to lead longer, healthier and more active lives. Cholestech provides easy to use, accessible diagnostic tools and information to health care practitioners in over 35 countries around the world. Cholestech offers efficient and economic diagnostic testing for cholesterol and related lipids, blood glucose and glycemic control, and liver enzymes at the point of care. Health care providers can use the CLIA-waived Cholestech LDX(R) and GDX(TM)* Systems and the hs-CRP test, which is cleared by the FDA for use in moderate complexity labs, to initiate and monitor the progress of patient therapy. By providing effective disease management solutions, Cholestech's goal is to be a leading provider of diagnostic tools and information for immediate risk assessment and therapeutic monitoring of heart disease, inflammatory disorders and diabetes. *The GDX system is 510(k) cleared for prescription home use and, accordingly, is CLIA waived.
Cholestech LDX is a registered trademark and Cholestech GDX is a trademark of Cholestech Corporation. All other trademarks mentioned in this document are the property of their respective owners. For more information about Cholestech and its products visit us on the web at www.cholestech.com.
CONTACT: Jack Glenn, Chief Financial Officer of Cholestech Corporation,+1-510-781-5065, or email@example.com; or investors, Brendan Lahiff ofFinancial Dynamics, +1-415-439-4504, or firstname.lastname@example.org, forCholestech Corporation